Latest Articles
Californian Is Sharing Her Endometriosis Journey for the First Time as She Preps for Her First New York City Marathon - Endometriosis Foundation of America
Californian Is Sharing Her Endometriosis Journey for the First Time as She Preps for Her First New York City Marathon Endometriosis Foundation of America
Published: Sept. 25, 2025, 6:21 p.m.
Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma - Frontiers
Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma Frontiers
Published: Sept. 25, 2025, 5:47 p.m.
Fibroblast Heterogeneity and FN1-Mediated Signaling in Endometriosis Revealed by Single-Cell and Spatial Transcriptomics - Frontiers
Fibroblast Heterogeneity and FN1-Mediated Signaling in Endometriosis Revealed by Single-Cell and Spatial Transcriptomics Frontiers
Published: Sept. 25, 2025, 5:33 p.m.
Early-Stage Endometrial Clear Cell Cancer Insights - Bioengineer.org
Early-Stage Endometrial Clear Cell Cancer Insights Bioengineer.org
Published: Sept. 25, 2025, 12:44 p.m.
Early-Stage Endometrial Clear Cell Cancer Insights - BIOENGINEER.ORG
Early-Stage Endometrial Clear Cell Cancer Insights BIOENGINEER.ORG
Published: Sept. 25, 2025, 12:44 p.m.
Academic researchers see a boost in interest — and innovation — around endometriosis - AAMC
Academic researchers see a boost in interest — and innovation — around endometriosis AAMC
Published: Sept. 25, 2025, 12:13 p.m.
CRT Boosts Survival in High-Risk Endometrial Cancer - Medscape
CRT Boosts Survival in High-Risk Endometrial Cancer Medscape
Published: Sept. 25, 2025, 10:18 a.m.
Swedish Biotech Gesynta Advances Non-Hormonal Endometriosis Treatment - insights.citeline.com
Swedish Biotech Gesynta Advances Non-Hormonal Endometriosis Treatment insights.citeline.com
Published: Sept. 25, 2025, 7:42 a.m.
The Global Progesterone Test for Endometrial Cancer Market - openPR.com
The Global Progesterone Test for Endometrial Cancer Market openPR.com
Published: Sept. 25, 2025, 6:22 a.m.
Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer OncLive
Published: Sept. 24, 2025, 7:04 p.m.
Link copied to clipboard!